These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22128783)

  • 1. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
    Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
    J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
    Liu T; Nair SJ; Lescarbeau A; Belani J; Peluso S; Conley J; Tillotson B; O'Hearn P; Smith S; Slocum K; West K; Helble J; Douglas M; Bahadoor A; Ali J; McGovern K; Fritz C; Palombella VJ; Wylie A; Castro AC; Tremblay MR
    J Med Chem; 2012 Oct; 55(20):8859-78. PubMed ID: 23025805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
    Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
    Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified silvestrol analogues with potent cytotoxic activity.
    Hawkins BC; Lindqvist LM; Nhu D; Sharp PP; Segal D; Powell AK; Campbell M; Ryan E; Chambers JM; White JM; Rizzacasa MA; Lessene G; Huang DC; Burns CJ
    ChemMedChem; 2014 Jul; 9(7):1556-66. PubMed ID: 24677741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation.
    Stanger KJ; Sliva D; Jiang J; Krchnák V
    Comb Chem High Throughput Screen; 2006 Nov; 9(9):651-61. PubMed ID: 17100571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α inhibitors: synthesis and biological evaluation of novel moracin O and P analogues.
    Xia Y; Jin Y; Kaur N; Choi Y; Lee K
    Eur J Med Chem; 2011 Jun; 46(6):2386-96. PubMed ID: 21481991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
    Thuaud F; Bernard Y; Türkeri G; Dirr R; Aubert G; Cresteil T; Baguet A; Tomasetto C; Svitkin Y; Sonenberg N; Nebigil CG; Désaubry L
    J Med Chem; 2009 Aug; 52(16):5176-87. PubMed ID: 19655762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
    Chang LS; Oblinger JL; Burns SS; Huang J; Anderson LW; Hollingshead MG; Shen R; Pan L; Agarwal G; Ren Y; Roberts RD; O'Keefe BR; Kinghorn AD; Collins JM
    Mol Cancer Ther; 2020 Mar; 19(3):731-741. PubMed ID: 31848295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
    Marastoni E; Bartoli S; Berettoni M; Cipollone A; Ettorre A; Fincham CI; Mauro S; Paris M; Porcelloni M; Bigioni M; Binaschi M; Nardelli F; Parlani M; Maggi CA; Paoli P; Rossi P; Fattori D
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1603-6. PubMed ID: 25746815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.